HK Stock Market Move | XIMEI RESOURCES (09936) surged nearly 8% as tantalum prices skyrocketed in the first half of the year. The development of advanced semiconductor manufacturing is expected to continue driving growth in the demand for tantalum target materials.
Ximei Resources (09936) rose nearly 8% in the morning session. As of the time of writing, it has increased by 7.8%, priced at HKD 12.72, with a trading volume of HKD 11.1238 million.
XIMEI RESOURCES (09936) rose nearly 8% in the morning, and as of the time of writing, it increased by 7.8%, trading at HKD 12.72, with a transaction volume of HKD 11.1238 million.
On the news front, the China Nonferrous Metals Industry Association released the latest statistics showing that in the first half of this year, the production of ten types of nonferrous metals reached 41.513 million tons, a year-on-year increase of 3.3%, according to the National Bureau of Statistics. The total profit of large-scale nonferrous enterprises reached CNY 418.39 billion, soaring by 94.0% year-on-year, making the profit growth rate one of the highest in the industrial sector. Driven by the demand from artificial intelligence computing infrastructure, the demand for "computing metals" has surged, with significant price increases in nonferrous metals such as copper, aluminum, tin, tantalum, and indium. Among them, the price of tin rose by 40% within six months, tantalum skyrocketed by 158%, and indium increased by 60%.
Sinolink pointed out that the global resource supply concentration is high, and supply disturbances occur frequently. The development of AI servers and advanced semiconductor manufacturing is expected to continue to drive demand growth in areas such as molybdenum capacitors and tantalum target materials. In the context of ongoing supply constraints and gradually increasing demand, the tantalum market is expected to shift from being supply-driven to a resonance of supply and demand, further raising the price center of molybdenum.
Related Articles

CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.

RECOMMEND





